Skip to main content

Table 3 Inequalities in patient-provider interaction and treatment received

From: Quality of care for the treatment for uncomplicated malaria in South-East Nigeria: how important is socioeconomic status?

  Poorest 40% Third 20% Fourth 20% Richest 20% All P-value
n (%) [95% CI]* n (%) [95% CI]* n (%) [95% CI]* n (%) [95% CI]* n (%) [95% CI]*
  N = 362 N = 292 N = 423 N = 565 N = 1642  
Nature of interaction
Told HW about fever(a) 312 (75.2) [61.0-85.5] 220 (54.7) [42.1-66.6] 248 (44.1) [36.3-52.2] 255 (36.1) [25.9-47.7] 1035 (44.3) [37.3-51.4] <0.001
HW asked questions about illness(b) 252 (59.9) [47.8-70.9] 184 (41.7) [27.9-56.9] 211 (36.2) [28.6-44.6] 228 (29.7) [20.2-41.3] 875 (35.7) [29.1-43.1] 0.011
Patient was physically examined 116 (21.9) [13.6-33.2] 101 (14.8) [9.2-22.9] 85 (7.6) [4.4-13.1] 101 (9.8) [5.7-16.2] 403 (10.8) [7.9-14.5] 0.031
Patient had temperature taken 98 (16.8) [9.7-27.5] 69 (7.6) [4.6-12.2] 49 (3.4) [2.0-5.7] 54 (4.4) [1.9-9.8] 270 (5.5) [3.9-7.8] 0.007
Patient was tested for malaria 7 (1.0) [0.6-1.7] 6 (1.0) [0.7-1.4] 3 (0.2) [0.1-0.6] 11 (0.8) [0.3-2.3] 27 (0.7) [0.3-1.3] 0.076
Requested a specific medicine 54 (23.3) [13.4-37.4] 85 (49.0) [36.8-61.4] 215 (63.6) [54.7-71.7] 328 (68.1) [57.2-77.4] 682 (60.5) [53.7-66.9] <0.001
For those that requested specific medicine, type of treatment requested N = 676
Antimalarial(c) 27 (69.5) [40.2-88.5) 69 (81.3) [56.6-93.5) 195 (93.7) [86.4-97.2] 295 (89.1) [82.1-93.5) 586 (89.1) [83.1-93.1] 0.057
ACT(c) 6 (26.2) [5.9-66.6] 12 [13.8) [5.6-30.1] 46 (24) [14.7-36.7) 85 (27.0) [18.6-37.5] 149 (24.5) [17.7-32.9] 0.458
Artesunate monotherapy(c) 2 (3.9) [0.5-23.9] 11 (13.8) [5.6-30.4) 39 (18.7) [12.3-27.3] 61 (18.5) [13.4-25.1] 113 (17.6) 13.6-22.4) 0.452
Sulphadoxine Pyrimethamine(c) 13 (32.1) [11.7-62.8] 35 (41.8) [25.0-60.7] 89 (43.4) [33.9-53.4] 126 (37.9) [28.3-48.5] 263 (39.9) [33.0-47.3] 0.741
Other type of antimalarial(c) 6 (7.3) [2.1-22.1] 11 (11.9) [4.8-26.6] 21 (7.7) [3.8-15.0] 23 (5.7) [3.3-9.5] 61 (7.1) [4.9-10.2] 0.395
Antibiotic(c) 7 (7.8) [2.7-20.6] 5 (8.7) [2.0-30.9] 8 (5.0) [1.9-12.1] 21 (6.1) [3.0-12.0] 41 (6.1) [3.5-10.4] 0.775
Antipyretic(c) 19 (31.7) [16.1-52.8] 38 (46.3) [30.4-62.9] 101 (45.9) [35.8-56.4] 162 (50.0) [40.8-59.2] 320 (47.7) [41.1-54.5] 0.563
For those that requested specific medicine, treatment received N = 586
Antimalarial 22 (93.8) [80.8-98.2] 64 (96.5) [86.1-99.2] 190 (98.0) [92.5-99.5] 274 (93.4) [82.0-97.8] 550 (95.3) [89.8-97.9] 0.265
ACT 5 (96.7) [74.5-99.7] 9 (74.4) [22.5-96.7] 43 (95.7) [79.0-99.2] 68 (83.7) [54.3-95.7] 125 (87.3) [67.6-95.8] 0.235
Artesunate monotherapy 1(77.9) [12.6-98.9] 10 (87.8) [27.4-99.3] 37 (94.2) [67.4-99.2] 49 (85.0) [57.2-91.3] 97 (85.0) [68.8-93.6] 0.316
Sulphadoxine Pyrimethamine 11 (94.4) [71.9-99.1] 32 (97.2) [86.3-99.5] 86 (96.3) [83.0-99.3] 120 (96.2) [86.8-99.0] 249 (96.3) [91.4-98.5] 0.948
Other type of antimalarial(c) 3 (66.1 [23.5-92.5] 9 (81.2) [29.4-97.8) 15 (64.7) [30.8-88.3] 17 (75.6) [54.9-85.2] 44 (72.5) [54.9-85.2] 0.789
Antibiotic(c) 5 (70.7) [30.7-92.9] 5 (100) 7 (90.3) [41.5-99.2] 19 (89.2) [42.5-98.9] 36 (90.6) [64.7-98.1] 0.704
Antipyretic(c) 17 (93.2) [70.3-98.8] 36 (89.9) [65.9-97.6] 97 (94.4) [81.1-98.5] 154 (96.2) [90.6-98.5] 304 (94.9) [88.6-97.8] 0.444
Treatment received for all febrile patients N = 1642
Antimalarial 179 (58.1) [46.01-69.3] 184 (71.9) [60.5-81.1] 339 (87.0) [80.7-91.5] 424 (80.1) [72.1-86.2] 1126 (79.3) [74.5-83.4] <0.001
ACT 38 (11.3) [4.6-24.9] 58 (18.1) [10.3-29.8] 91 (22.0) [15.1-30.8] 128 (25.7) [19.3-33.4] 315 (22.4) [17.0-28.8] 0.100
Artesunate monotherapy 10 (3.5) [1.3-9.2] 22 (9.9) [4.8-19.1] 44 (13.2) [8.8-19.3] 82 (16.2) [12.1-21.3] 158 (13.4) [10.6-16.7] 0.053
Sulphadoxine Pyrimethamine 84 (30.7) [20.3-43.6] 82 (35.6) [24.8-48.2] 178 (45.8) [36.4-55.5] 192 (34.6) [26.4-43.9] 536 (37.9) [31.9-44.3] 0.117
Other type of antimalarial 47 (12.6) [7.3-20.9] 27 (10.9) [6.1-18.7] 29 (6.8) [3.6-12.4] 42 (7.4) [4.7-11.5] 145 (8.2) [6.1-10.7] 0.327
Antibiotic 76 (16.0) [10.7-23.3] 39 (10.8) [5.6-19.8] 27 (6.8) [3.8-11.7] 51 (8.4) [5.6-12.5] 193 (8.8) [6.8-11.3) 0.138
Antipyretic 226 (59.4) [49.3-68.7] 167 (56.7) [44.1-68.4] 211 (52.3) [42.6-61.8] 270 (50.8) [43.3-58.3] 875 (52.8) [47.7-57.8] 0.584
For those that received ACT
Received ACT in correct dose 25 (56.5) [17.4-88.9] 47 (77.0) [53.2-90.8] 48 (62.4) [42.6-78.7] 81 (67.7) [45.3-84.2] 201 (67.0) [53.3-78.2] 0.716
Patient knows regimen 20 (48.1) [15.2-82.7] 41 (72.4) [47.8-88.2] 41 (54.3) [31.3-75.6] 67 (59.8) [36.4-79.5] 169 (59.5) [43.7-73.5] 0.655
  1. *Population averaged percentages and corresponding 95% confidence intervals, which have been adjusted for the survey design. (a)Missing one response (b)Missing two responses (c)Missing 11 responses.